Corcept Therapeutics Announces First Quarter 2020 Financial Results And Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Corcept Therapeutics (CORT) Tops Q1 EPS by 12c, Revenues Beat; Offers FY20 Revenue Mid-Point Guidance Above Consensus
May 4, 2020 4:51 PM EDTCorcept Therapeutics (NASDAQ: CORT) reported Q1 EPS of $0.34, $0.12 better than the analyst estimate of $0.22. Revenue for the quarter came in at $93.2 million versus the consensus estimate of $87.01 million.
Financial Highlights
Revenue of $93.2 million, a 44 percent increase from first quarter 2019GAAP diluted net income of $0.25 per share, compared to $0.15 per share in first quarter 2019Non-GAAP diluted net income of $0.34 per share, compared to $0.20 per share in first quarter 2019Cash and investments of $349.0 million, compared to $315.3 million in fourth quarter 2019Our commercial and medical affairs teams did an excellent... More
